Mouchel Parkman, manager of the M25 motorway, stood out with a rise of 12p to 247½p with profits before tax up by 30% at £7.9m and a rise in the dividend. On the Alternative Investment Market (Aim), Sinclair Pharma shot up 10p to 131½p, after US drug regulators approved Decapinol, its mouth rinse for gum disease gingivitis. The market is reckoned to be worth $100m a year and Nomura says Decapinol will be one of the group's biggest growth drivers.